Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

The First Affiliated Hospital of Chongqing Medical University

5 abstracts

Abstract
Hepatic artery infusion chemotherapy (HAIC) combined with tislelizumab and lenvatinib for initial unresectable hepatocellular carcinoma (HCC) with portal vein tumor thrombus: A prospective, single-arm phase II trial.
Org: The First Affiliated Hospital of Chongqing Medical University,
Abstract
Clinical efficacy of avapritinib in gastrointestinal stromal tumors (GIST) with different KIT genotypes: Post hoc analysis of the phase 1 NAVIGATOR and phase 1/2 CS3007-101 trials.
Org: Portland VA Health Care System, OHSU Knight Cancer Institute, Portland, OR, Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, The First Affiliated Hospital of Sun Yat-sen University,
Abstract
A phase Ib/II study to assess the safety and preliminary efficacy of PM8002 in combination with nab-paclitaxel in patients with triple-negative breast cancer.
Org: Fudan University Shanghai Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Harbin Medical University Cancer Hospital, The First Affiliated Hospital of Chongqing Medical University,
Abstract
Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors (GIST) as ≥4th line therapy: Long-term update from a single-arm, phase 2 trial.
Org: Peking University Cancer Hospital & Institute, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Fujian Medical University Union Hospital, The First Affiliated Hospital of Chongqing Medical University, Fudan University Shanghai Cancer Center,
Abstract
OS analysis of patients with different short-term response and progression patterns of donafenib versus sorafenib as first-line therapy for advanced hepatocellular carcinoma: An exploratory subgroup analysis of ZGDH3.
Org: Jinling Hospital of Nanjing University of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, China, West China Hospital, Sichuan University,